Ekerljung Linda, Bjerg Anders, Bossios Apostolos, Axelsson Malin, Torén Kjell, Wennergren Göran, Lötvall Jan, Lundbäck Bo
Krefting Research Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Box 424, SE 40530 Gothenburg, Sweden.
Krefting Research Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Box 424, SE 40530 Gothenburg, Sweden.
Respir Med. 2014 May;108(5):685-93. doi: 10.1016/j.rmed.2014.02.016. Epub 2014 Mar 14.
Asthma medication was increasingly used during the second part of the past century. There are few detailed data from population studies on use of asthma medication. The current study aimed to determine the use and determinants of asthma medication in West Sweden and to assess changes during the last two decades.
From a random population sample participating in a survey on respiratory symptoms, 2000 individuals were randomly selected for clinical examinations and structured interviews, 1172 participated. All subjects reporting asthma (n = 1524) were also invited, and 834 participated. In total, 964 subjects with asthma participated. Asthma medication use was assessed in the general population and among two severity categories of asthma: multi-symptom asthma (MSA) and "other" asthma (having fewer symptoms). Current data, from 2010, was compared with data from 1992.
Asthma medication was used by 11% of the population, 4.4% used ICS with concurrent use of LABA, 3.3% used ICS without LABA, while 3.2% only used SABA. Compared with 1992, the prevalence of asthma medication use had increased with 54%, and use of ICS had increased from 1.5% to 7.7%.
Subjects with MSA reported using asthma medication more frequently and at higher doses, and a higher proportion used ICS.A shift in asthma medication use has occurred since 1992, with increased use of ICS and decreased use of SABA only, implying better asthma control on a population level. Multi-symptom asthma should alert the treating physician to consider under-medication and/or poor treatment adherence.
哮喘药物在过去世纪后半叶的使用日益增多。关于哮喘药物使用的人群研究详细数据较少。本研究旨在确定瑞典西部哮喘药物的使用情况及影响因素，并评估过去二十年的变化。
从参与呼吸症状调查的随机人群样本中，随机选取2000人进行临床检查和结构化访谈，1172人参与。所有报告患有哮喘的受试者（n = 1524）也被邀请，834人参与。总计964名哮喘受试者参与。在普通人群以及哮喘的两种严重程度类别中评估哮喘药物使用情况：多症状哮喘（MSA）和“其他”哮喘（症状较少）。将2010年的当前数据与1992年的数据进行比较。
11%的人群使用哮喘药物，4.4%使用吸入性糖皮质激素（ICS）并同时使用长效β2受体激动剂（LABA），3.3%使用ICS但未使用LABA，而3.2%仅使用短效β2受体激动剂（SABA）。与1992年相比，哮喘药物使用患病率增加了54%，ICS的使用从1.5%增加到7.7%。
患有MSA的受试者报告更频繁且更高剂量地使用哮喘药物，且更高比例的人使用ICS。自1992年以来哮喘药物使用发生了转变，ICS使用增加而仅SABA使用减少，这意味着在人群层面哮喘控制得到改善。多症状哮喘应提醒治疗医生考虑用药不足和/或治疗依从性差的问题。
